



30th June 2021

Quantum Health Group Limited (ASX:QTM) Share Capital Reduction under Section 258F

Quantum Health Group Limited (Quantum or the Company) advises that the Quantum Board has resolved to reduce the share capital of the Company by \$68,977,000 in accordance with Section 258F of the Corporations Act, 2001(Cth) (Corporations Act).

Under section 258F of the Corporations Act, a company may reduce its share capital without shareholder approval by cancelling any paid-up share capital that is not represented by available assets. The Company's historical activities, including prior business restructures and discontinued operations in sectors unrelated to the Company's Healthcare Sector focus, have resulted in the Company's net assets being less than the share capital. The share capital reduction under section 258F approved by the Board results in the issued share capital and the prior year accumulated accounting losses balances in the Company's financial statements being reduced by \$68,977,000, such that the financial statements are more representative of the current Healthcare Sector operations and assets of the Company and the Quantum Group.

The share capital reduction is a technical accounting adjustment only, related to trading activities of unrelated businesses prior to 2005, and has no impact on the net assets, financial results, cash flow, funding, operations or financial performance of the Quantum Health Group.

There is no impact on shareholders from the share capital reduction as no shares will be cancelled or rights varied. The number of securities on issue will not change as a result of the share capital reduction.

In accordance with ASX Listing Rule 7.20, the Company is required to make the following disclosures in relation to the share capital reduction:

- The share capital reduction has no impact on the number of issued securities in the Company (nor the amount unpaid (if any) on such securities);
- There are no fractional entitlements arising from the share capital reduction; and
- As the Company has no convertible securities on issue – there is no impact on the treatment of convertible securities arising from the share capital reduction.

Authorised for lodgement by Mr John Walstab, CEO/Managing Director, Quantum Health Group Limited.

Mr John Walstab

T: 1 800 228 118

E: jwalstab@qhealthcare.com.au

About Quantum Health Group Limited

Quantum Health Group Limited (ASX:QTM) is a leading independent Healthcare company operating throughout Asia. Quantum Healthcare specialise in the distribution of state of the art medical imaging, patient treatment, hospital water sterilisation and equipment services in Radiology, Oncology and Women's Healthcare. Quantum Healthcare's head office is located in Sydney, Australia with direct subsidiary businesses operating in Thailand, South Korea, Philippines, NZ and China. Quantum is the authorised distribution partner for leading global healthcare manufacturers including Carestream, Philips Healthcare, Samsung, IBA and Accuray. Quantum Healthcare has successfully created a Healthcare Technology Platform across Asia and it provides first class customer service and clinical support for a large installed base of medical equipment in hospitals, universities and private clinics.